Amyloidosis - 257 Studies Found
| Completed |
: Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis : Amyloidosis : 2006-03-01 : Drug: VELCADE Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2 |
| Recruiting |
: Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis : Cardiac Amyloidosis : 2016-06-09 |
| Recruiting |
: The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis : Cardiac Amyloidosis : 2017-01-31 : Drug: F-18 florbetapir Cardiac PET images will be obtained following injection of F-18 labeled Florbetap |
| Recruiting |
: Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis : Dialysis Amyloidosis : 2016-10-30 : Device: Lixelle® treatment The treatment will be performed with the Lixelle® column connected |
| Recruiting |
: Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis : Cardiac Amyloidosis : 2016-11-08 :
|
| Completed |
: A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis : TTR-mediated Amyloidosis : 2014-11-10 : Drug: Revusiran (ALN-TTRSC) |
| Completed |
: Trial to Evaluate Safety and Tolerability of ALN-TTR02 in Transthyretin (TTR) Amyloidosis : TTR-mediated Amyloidosis : 2012-06-07 : Drug: ALN-TTR02 Ascending doses of ALN-TTR02 administered by intravenous (IV) infusion |
| Completed |
: Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis : TTR-mediated Amyloidosis : 2013-11-06 : Drug: ALN-TTRSC (revusiran) for subcutaneous administration |
| Completed |
: Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis : Transthyretin Mediated Amyloidosis (ATTR) : 2010-06-21 :
|
| Active, not recruiting |
: The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis : Primary Systemic (AL) Amyloidosis : 2014-12-02 :
|